secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2024-01-18T23:59:59+00:00
Accession:  0001819790-24-000006
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus CMO Jose Trevejo departs; clinical dev reorganizes under COO
-------------------------------------------------------------------

- Dr. Trevejo steps down as CMO effective Jan 18, 2024; employment ends Feb 17, 2024.
- Clinical development and medical affairs reorganized under COO Dr. Sesha Neervannan.
- Transition approved Jan 11, 2024; company expresses gratitude for Dr. Trevejo's service.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979024000006/0001819790-24-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979024000006/tars-20240111.htm
  HTML page:      https://secwatch.observer/filing/0001819790-24-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer